Antagonists of interleukin-15
US6013480A · kind A · utility
28Cited by
8References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 14, 1998 |
| Grant date | Jan 11, 2000 |
| Priority date | — |
| Expiry date | Aug 14, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.